Humacyte (HUMA) experienced a decline of 1.94% in its latest trading session, closing at $5.05, which was slightly more than the S&P 500's 1.86% daily loss. Over the past month, Humacyte's shares have...
Kathleen Sebelius, a director at Humacyte ($HUMA), sold 1,548 shares of the company on 09-10-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 3.6% of their...
Humacyte (HUMA), a biotechnology firm specializing in acellular tissue-engineered vessels, recently encountered significant challenges due to regulatory issues with the U.S. FDA. Following reports of FDA...
Benchmark analyst Bruce Jackson maintained a Buy rating on Humacyte (HUMA) with a price target of $15.00, suggesting a significant upside for the company’s stock. Humacyte shares closed at $5.39 yesterday,...
Humacyte is a pre-revenue biotech company that has delivered outsized gains to shareholders in 2024. But is the small-cap stock a good buy right now?
On April 16th, we reported on a stock trade by Senator Tommy Tuberville that looked suspicious to us. The stock has now risen 220% in the month since then. The stock in question was Humacyte, $HUMA. It's...